Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Memory T cell–driven differentiation of naive cells impairs adoptive immunotherapy
Christopher A. Klebanoff, … , Richard M. Siegel, Nicholas P. Restifo
Christopher A. Klebanoff, … , Richard M. Siegel, Nicholas P. Restifo
Published December 14, 2015
Citation Information: J Clin Invest. 2016;126(1):318-334. https://doi.org/10.1172/JCI81217.
View: Text | PDF
Research Article Immunology Oncology Article has an altmetric score of 28

Memory T cell–driven differentiation of naive cells impairs adoptive immunotherapy

  • Text
  • PDF
Abstract

Adoptive cell transfer (ACT) of purified naive, stem cell memory, and central memory T cell subsets results in superior persistence and antitumor immunity compared with ACT of populations containing more-differentiated effector memory and effector T cells. Despite a clear advantage of the less-differentiated populations, the majority of ACT trials utilize unfractionated T cell subsets. Here, we have challenged the notion that the mere presence of less-differentiated T cells in starting populations used to generate therapeutic T cells is sufficient to convey their desirable attributes. Using both mouse and human cells, we identified a T cell–T cell interaction whereby antigen-experienced subsets directly promote the phenotypic, functional, and metabolic differentiation of naive T cells. This process led to the loss of less-differentiated T cell subsets and resulted in impaired cellular persistence and tumor regression in mouse models following ACT. The T memory–induced conversion of naive T cells was mediated by a nonapoptotic Fas signal, resulting in Akt-driven cellular differentiation. Thus, induction of Fas signaling enhanced T cell differentiation and impaired antitumor immunity, while Fas signaling blockade preserved the antitumor efficacy of naive cells within mixed populations. These findings reveal that T cell subsets can synchronize their differentiation state in a process similar to quorum sensing in unicellular organisms and suggest that disruption of this quorum-like behavior among T cells has potential to enhance T cell–based immunotherapies.

Authors

Christopher A. Klebanoff, Christopher D. Scott, Anthony J. Leonardi, Tori N. Yamamoto, Anthony C. Cruz, Claudia Ouyang, Madhu Ramaswamy, Rahul Roychoudhuri, Yun Ji, Robert L. Eil, Madhusudhanan Sukumar, Joseph G. Crompton, Douglas C. Palmer, Zachary A. Borman, David Clever, Stacy K. Thomas, Shashankkumar Patel, Zhiya Yu, Pawel Muranski, Hui Liu, Ena Wang, Francesco M. Marincola, Alena Gros, Luca Gattinoni, Steven A. Rosenberg, Richard M. Siegel, Nicholas P. Restifo

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2009 Total
Citations: 9 13 11 20 20 21 13 21 19 11 1 1 160
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2021 (20)

Title and authors Publication Year
Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells
JT Huckaby, E Landoni, TM Jacobs, B Savoldo, G Dotti, SK Lai
Journal for ImmunoTherapy of Cancer 2021
Improving CAR T-Cell Persistence
V Pietrobon, LA Todd, A Goswami, O Stefanson, Z Yang, F Marincola
International journal of molecular sciences 2021
Metabolic and Mitochondrial Functioning in Chimeric Antigen Receptor (CAR)—T Cells
AH M., JC Halpin, M Mollaei, SW Bell, N Hirankarn, AD McLellan
Cancers 2021
Adoptive T Cell Therapy for Solid Tumors: Pathway to Personalized Standard of Care
SS Qin, AD Melucci, AC Chacon, PA Prieto
Cells 2021
PI3K/Akt Pathway: The Indestructible Role of a Vintage Target as a Support to the Most Recent Immunotherapeutic Approaches
M Caforio, E de Billy, BD Angelis, S Iacovelli, C Quintarelli, V Paganelli, V Folgiero
Cancers 2021
Ion Channels Orchestrate Pancreatic Ductal Adenocarcinoma Progression and Therapy
V Hofschröer, K Najder, M Rugi, R Bouazzi, M Cozzolino, A Arcangeli, G Panyi, A Schwab
Frontiers in pharmacology 2021
A Correlation Between Differentiation Phenotypes of Infused T Cells and Anti-Cancer Immunotherapy
H Ren, K Cao, M Wang
Frontiers in immunology 2021
Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy
I Vanmeerbeek, DM Borras, J Sprooten, O Bechter, S Tejpar, AD Garg
Genes and Immunity 2021
Single-Cell TCR and Transcriptome Analysis: An Indispensable Tool for Studying T-Cell Biology and Cancer Immunotherapy
A Pasetto, YC Lu
Frontiers in immunology 2021
Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
S Chandrasekaran, CR Funk, T Kleber, CM Paulos, M Shanmugam, EK Waller
Frontiers in immunology 2021
PI3Kδ coordinates transcriptional, chromatin, and metabolic changes to promote effector CD8+ T cells at the expense of central memory
JL Cannons, AV Villarino, SM Kapnick, S Preite, HY Shih, J Gomez-Rodriguez, Z Kaul, H Shibata, JM Reilley, B Huang, R Handon, IT McBain, S Gossa, T Wu, HC Su, DB McGavern, JJ OShea, PJ McGuire, G Uzel, PL Schwartzberg
Cell Reports 2021
CD95L and Anti-Tumor Immune Response: Current Understanding and New Evidence
DM Richards, C Merz, C Gieffers, A Krendyukov
Cancer management and research 2021
Fas/FasL Signaling Regulates CD8 Expression During Exposure to Self-Antigens
G Flores-Mendoza, N Rodríguez-Rodríguez, RM Rubio, IK Madera-Salcedo, F Rosetti, JC Crispín
Frontiers in immunology 2021
Homeostatic cytokines tune naivety and stemness of cord blood-derived transgenic T cells
C Marton, P Mercier-Letondal, R Loyon, O Adotévi, C Borg, J Galaine, Y Godet
Cancer Gene Therapy 2021
Exercise and the immune system: taking steps to improve responses to cancer immunotherapy
MP Gustafson, CM Wheatley-Guy, AC Rosenthal, DA Gastineau, E Katsanis, BD Johnson, RJ Simpson
Journal for ImmunoTherapy of Cancer 2021
Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers
Z Yang, L Li, A Turkoz, P Chen, R Harari-Steinfeld, M Bobbin, O Stefanson, H Choi, V Pietrobon, B Alphson, A Goswami, V Balan, A Kearney, D Patel, J Yang, D Inel, V Vinod, A Cesano, B Wang, KH Roh, LS Qi, FM Marincola
Journal of Translational Medicine 2021
Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL
B Deng, J Pan, Z Liu, S Liu, Y Chen, X Qu, Y Zhang, Y Lin, Y Zhang, X Yu, Z Zhang, X Niu, R Luan, M Ma, X Li, T Liu, , H Niu, AH Chang, C Tong
Molecular Therapy — Methods & Clinical Development 2021
Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials
S Smirnov, A Petukhov, K Levchuk, S Kulemzin, A Staliarova, K Lepik, O Shuvalov, A Zaritskey, A Daks, O Fedorova
Frontiers in immunology 2021
Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells
W Gong, L Wang, S Stock, M Ni, M Schubert, B Neuber, C Kleist, A Hückelhoven-Krauss, D Wu, C Müller-Tidow, A Schmitt, H Shiku, M Schmitt, L Sellner
Cells 2021
LFA-1 in T cell priming, differentiation, and effector functions
Gerard A, Cope AP, Kemper C, Alon R, Köchl R
Trends in Immunology 2021

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 33 X users
Referenced in 19 patents
On 2 Facebook pages
Mentioned in 1 Google+ posts
337 readers on Mendeley
See more details